Audentes Therapeutics (NASDAQ: BOLD) is one of 293 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Audentes Therapeutics to related businesses based on the strength of its profitability, institutional ownership, risk, earnings, analyst recommendations, valuation and dividends.
This is a breakdown of current ratings and target prices for Audentes Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Audentes Therapeutics Competitors||746||3053||11557||246||2.72|
Audentes Therapeutics currently has a consensus target price of $24.40, indicating a potential downside of 12.95%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 30.25%. Given Audentes Therapeutics’ competitors higher possible upside, analysts clearly believe Audentes Therapeutics has less favorable growth aspects than its competitors.
Risk & Volatility
Audentes Therapeutics has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, Audentes Therapeutics’ competitors have a beta of 6.63, indicating that their average stock price is 563% more volatile than the S&P 500.
Institutional & Insider Ownership
77.1% of Audentes Therapeutics shares are owned by institutional investors. Comparatively, 50.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 47.3% of Audentes Therapeutics shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Audentes Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Audentes Therapeutics Competitors||-5,488.05%||-450.45%||-42.07%|
Earnings and Valuation
This table compares Audentes Therapeutics and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Audentes Therapeutics||N/A||-$73.43 million||-7.90|
|Audentes Therapeutics Competitors||$330.89 million||$94.72 million||-7.18|
Audentes Therapeutics’ competitors have higher revenue and earnings than Audentes Therapeutics. Audentes Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.